Media Thread, page-15723

Hi @Outlander2

Thanks foryour thoughts and the ** on Vaxinia.

To me thevalue from the MAST trial has now passed. The sand box trial has shown CF33 issafe, has now been approved in a meaningful dosage to allow the virus to work,and has allowed FDA to get comfortable with the compound. The optimal dose ofCF33 could still go many logs higher. But the current dose is sufficient and isworking as well as I feel CF33 can as in mono therapy.

Where tofrom here?

The rub forme is that the virus to date has not been powerful enough to kill cancer in astandalone method of action. Pre-clinically it obliterated all 60 lines ofcancer, though in humans simply put it is not. The complete response was achievedat a mid-dose. As dosage has escalated, we haven’t seen a corresponding increasein efficiency in the patients. Stable disease appears the most common outcome apatient can expect. (The virus is able to control cancer but not kill it).

As reinforcedby YF comments the virus needs the bodies own immune system to also attack thecancer in tandem, or a third method of action of chemo or T cell therapy. Forthe virus to succeed in clinical trials as mono it requires healthy patientswith healthy immune systems. We may get lucky on Bile Duct cancer, being no currentstandard of care. Patients will qualify and enrol in the trial before theyhave failed off multiple lines of chemo and become too unwell.

Immune doesnot have unlimited resources to run trials and explore all the science (sadly).The company needs to be priorities its best commercial outcomes first. And that’sleaving MAST where it is focus on Phase 1B Bile Duct, Azercel, and onCARltyics –which is thankfully what management appear to be doing.

I think it’stelling the cohorts enrolments in MAST have not progressed now for 12-18months. Especially the combo arms with Pembro. If they were seeing strong outcomes,they would have kept going. The sand box trial was a good idea as a first step.But its time now for the company to cut it back down to size and finish it.

DYOR not advice